These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33393027)

  • 1. ASO Author Reflections: Clinical Implications of Circulating Tumor DNA in Pancreatic Cancer Patients.
    Yamaguchi T; Uemura K; Takahashi S
    Ann Surg Oncol; 2021 Jun; 28(6):3145-3146. PubMed ID: 33393027
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status.
    Xie H; Kim RD
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):890. PubMed ID: 32812106
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
    Baumgartner JM; Riviere P; Kurzrock R
    Ann Surg Oncol; 2020 Sep; 27(9):3268-3269. PubMed ID: 32303875
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.
    Fang Z; Meng Q; Zhang B; Shi S; Liu J; Liang C; Hua J; Yu X; Xu J; Wang W
    Aging (Albany NY); 2020 Dec; 13(2):2031-2048. PubMed ID: 33318293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?
    Gögenur M; Lindbjerg Andersen C; Gögenur I
    Ann Surg Oncol; 2022 Dec; 29(13):8675. PubMed ID: 35930114
    [No Abstract]   [Full Text] [Related]  

  • 7. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer.
    Imamura T; Ashida R; Urakami K; Ohshima K; Uesaka K; Sugiura T; Okamura Y; Ohgi K; Yamada M; Otsuka S; Nagashima T; Sugino T; Akiyama Y; Yamaguchi K
    Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38447210
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis.
    Baumgartner JM; Kurzrock R
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):772-773. PubMed ID: 30421042
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
    Sugimori M; Sugimori K; Tsuchiya H; Suzuki Y; Tsuyuki S; Kaneta Y; Hirotani A; Sanga K; Tozuka Y; Komiyama S; Sato T; Tezuka S; Goda Y; Irie K; Miwa H; Miura Y; Ishii T; Kaneko T; Nagahama M; Shibata W; Nozaki A; Maeda S
    Cancer Sci; 2020 Jan; 111(1):266-278. PubMed ID: 31746520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Perioperative Genomic Profiles and Prognosis of Peripheral and Perihepatic Circulating Tumor DNA in Patients with Colorectal Liver Metastases.
    Narayan RR; Kingham TP
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):583-584. PubMed ID: 30989499
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Potential Values of Peritoneal Cell-Free Tumor DNA Testing.
    Chan CHF
    Ann Surg Oncol; 2020 Dec; 27(13):5072-5073. PubMed ID: 33078317
    [No Abstract]   [Full Text] [Related]  

  • 12. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASO Author Reflections: Clinical Significance of Large Tenascin C Splice Variants and Annexin A2 for Pancreatic Cancer.
    Hagiwara K; Harimoto N; Shirabe K
    Ann Surg Oncol; 2020 Mar; 27(3):931-932. PubMed ID: 31758283
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Challenges of Circulating Tumor DNA in the Management of Gastrointestinal Peritoneal Carcinomatosis.
    Sullivan BG; Dayyani F; Senthil M
    Ann Surg Oncol; 2023 Jan; 30(1):285-286. PubMed ID: 36100836
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.
    Gall TMH; Belete S; Khanderia E; Frampton AE; Jiao LR
    Am J Pathol; 2019 Jan; 189(1):71-81. PubMed ID: 30558725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
    Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
    Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.